Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis

Table 1 Baseline characteristics of the included studies

Study	Age (yr)	Drug and dose	Case	Severity	Treatment	Duration (wk)
ACT 1	41.4 ± 13.7	Placebo	121	Moderate to-severe active UC	Intravenous infusions at weeks 0, 2 and 6 and then every eight weeks or matching placebo	54
(Rutgeerts et al[16], Feagan et al[17], Sandborn et al[18])	42.4 ± 14.3	Infliximab 5 mg/kg	121
	41.8 ± 14.9	Infliximab 10 mg/kg	122
ACT 2	39.3 ± 13.5	Placebo	123	Moderate-to-severe active UC	Intravenous infusions at weeks 0, 2 and 6 and then every eight weeks or matching placebo	30
(Rutgeerts et al[16], Feagan et al[17], Sandborn et al[18])	40.5 ± 13.1	Infliximab 5 mg/kg	121
	40.3 ± 13.3	Infliximab 10 mg/kg	120
Suzuki et al[19]	41.3 ± 13.6	Placebo	96	Moderate-to-severe active UC	Subcutaneous injections 160/80 mg at week 0, 80/40 mg at week 2 and then 40 mg beginning at week 4 every other week or matching placebo	52
	44.4 ± 15.0	Adalimumab 80/40 mg	87
	42.5 ± 14.6	Adalimumab 160/80 mg	90
ULTRA 2	41.3 ± 13.2	Placebo	246	Moderate-to-severe active UC	Subcutaneous injections 160 mg at week 0, 80 mg at week 2 and then 40 mg beginning at week 4 every other week or matching placebo	52
(Sandborn et al[20])	39.6 ± 12.5	Adalimumab	248			8
Reinisch et al[21]	37.0 ± 9.0	Placebo	130	Moderate-to-severe active UC	Subcutaneous injections 160/80 mg at week 0, 80/40 mg at week 2 and then 40 mg beginning at week 4 every other week or matching placebo
	40.0 ± 9.5	Adalimumab 80/40 mg	130
	36.5 ± 9.5	Adalimumab 160/80 mg	130			6
PURSUIT-SC	39.0 ± 13.0	Placebo	331	Moderate-to-severe active UC	Subcutaneous injections 400/200 mg at week 0 and 200/100 at week 2 or matching placebo
(Sandborn et al[12])	40.0 ± 13.5	Golimumab 200/100 mg	331
	40.7 ± 13.7	Golimumab 400/200 mg	331			54
PURSUIT-M	40.2 ± 14.1	Placebo	156	Moderate-to-severe active UC	Subcutaneous injections 100/50 mg every 4 wk or matching placebo
(Sandborn et al[13])	41.4 ± 13.8	Golimumab 50 mg	154
	39.1 ± 13.1	Golimumab 100 mg	154			52
GEMINI 1	41.2 ± 12.5	Placebo	149	Moderate-to-severe active UC	Intravenous infusions every 4 wk or every 8 wk or matching placebo
(Feagan et al[9,14])	40.1 ± 13.2	Vedolizumab 300 mg	746

Table 2 Heterogeneity analysis of the biological agents compared to placebo (%)

	Response		Remission		Mucosal healing		Serious adverse events
	Induction	Maintenance	Induction	Maintenance	Induction	Maintenance	Maintenance
Infliximab	0	0	47.4	0	0	0	0
Adalimumab	0	0	0	0	0	0	0
Golimumab	0	0	0	0	0	0	0
Vedolizumab	-	0	-	0	-	0	-